The raised funds, totaling USD 40 million, will be used to accelerate the company’s growth and to advance its robotic platform, Constellation, which enables flexible, scalable cell therapy manufacturing.

As demand for GLP-1 obesity drugs surges and affordability remains a competitive factor in the global weight-loss market, Eli Lilly slashes tirzepatide vial prices to boost access for self-pay patients.

A fundamental, digitally driven overhaul of bio/pharmaceutical manufacturing models are needed to meet the demands of current global supply chain pressures and rising complexity of novel therapeutics.

As a settlement is finally agreed upon for Purdue Pharma and the Sackler family, the pharma industry needs to increase transparency and accountability to ensure profits are not prioritized over public health again.

Yaohui Ji brings nearly two decades of leadership experience as BioDuro strengthens its integrated contract research, development, and manufacturing organization (CRDMO) platform for small and large molecule development.

The Big Pharma companies have voluntarily agreed to a range of measures to reduce the cost of medicines for American patients while also preserving the biopharmaceutical innovation ecosystem of the U.S.

The Polish company debuts as a European biologics CDMO, offering services from accelerated development through to commercialization using advanced digital tools and mirrored GMP-certified sites.

Innovator companies are increasingly engaging with outsourcing partners in efforts to improve cost and time efficiencies across the complete drug development lifecycle.

Luke Miels, the company’s current Chief Commercial Officer, has been appointed as the new CEO, signaling the company’s next phase after Dame Emma Walmsley’s era of strategic growth and innovation.

While the levies seem steep the impact on industry may be less severe than expected as many companies have a presence or are planning works for manufacturing facilities within the U.S., making them exempt from the tariffs.

Several big players within the bio/pharma industry are pulling back their investments from the United Kingdom amid fears over the security of the country’s life sciences environment.

In this guest blog post, Will Downie and Elliott Berger delve into the key factors that are negatively impacting CDMO revenue performance and highlight the foundational elements that should be adopted to ensure success.

The global healthcare company is expecting that its efforts to streamline operations will allow it to improve the speed of decision making and reinvest savings into pertinent growth opportunities.

Industry leaders delve into the latest biopharma supply chain disruptions and provide insights into approaches that can help to reduce vulnerabilities and ensure greater resilience in the future.

As pharmaceutical packaging evolves to incorporate more patient-centric designs, overcome increasingly complex formulations, and undergo a digital transformation, safety and compliance remain non-negotiables.

D’Herve has succeeded Dr. Singh, bringing a wealth of industry experience to the position, having previously served in senior positions at Evonik.

Recent fatalities in clinical trials for gene therapies have led to greater regulatory scrutiny and concerns over safety, particularly in relation to the use of viral vectors, leading industry to question whether a potential therapeutic reinvention is needed.

In efforts to position itself for long-term growth, Rocket is reducing its company headcount, undergoing a structural reorganization, and prioritizing late-stage AAV cardiovascular programs.

The CDMO model is evolving to incorporate more innovative approaches and specialist capacity as a result of the increasingly complex development pipeline. In this article, The Pharma Navigator editors provide a snapshot of some of the news from CDMOs helping innovators with their formulation requirements.

Increasingly complex and diverse molecules in the development pipeline and greater demand for patient-centricity are leading to a need for developers to employ advanced formulation approaches and strategies.